Last update July 20, 2017

C41H76N2O15

Compatible

Safe substance and/or breastfeeding is the best option.

Less than 0.05% of the maternal dose of roxithromycin is excreted in milk (AEMPS 2002, Puri 1987).

Early exposure to macrolides (especially erythromycin, see specific information) has been linked to the occurrence of hypertrophic pyloric stenosis (Goldstein 2009, Chin 2001), including through breast milk, so it may be prudent to avoid them during the first month of breastfeeding.

Be aware of false negative results of bacterial cultures obtained from febrile infants whose mothers are on antibiotics, as well as the possibility of gastroenteritis due to altered intestinal flora (Ito 1993).


See below the information of this related product:

  • Erythromycin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

We do not have alternatives for C41H76N2O15 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C41H76N2O15 is Roxithromycin in Molecular formula.

Is written in other languages:

Group

C41H76N2O15 belongs to this group or family:

Tradenames

Main tradenames from several countries containing C41H76N2O15 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 837 daltons
Protein Binding 92 - 96 %
Tmax 1 - 2.2 hours
10.5 hours

References

  1. Sanofi. Roxithromycin. Drug Summary. 2012 Full text (in our servers)
  2. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract Full text (link to original source) Full text (in our servers)
  3. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during lactation. Breastfeed Med. 2009 Dec;4(4):197-200. Abstract
  4. AEMPS. Roxitromicina. Ficha técnica. 2002 Full text (in our servers)
  5. Chin KG, McPherson CE 3rd, Hoffman M, Kuchta A, Mactal-Haaf C. Use of anti-infective agents during lactation: Part 2--Aminoglycosides, macrolides, quinolones, sulfonamides, trimethoprim, tetracyclines, chloramphenicol, clindamycin, and metronidazole. J Hum Lact. 2001 Feb;17(1):54-65. Abstract
  6. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  7. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989 Abstract
  8. Puri SK, Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother. 1987 Abstract

Total visits

1,962

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM